| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371455 | Bioorganic & Medicinal Chemistry Letters | 2011 | 5 Pages |
Abstract
Rho kinase (ROCK) is an attractive therapeutic target for various diseases including glaucoma, hypertension, and spinal cord injury. Herein, we report the development of a series of ROCK-II inhibitors based on 4-quinazolinone and quinazoline scaffolds. SAR studies at three positions of the quinazoline core led to the identification of analogs with high potency against ROCK-II and good selectivity over protein kinase A (PKA).
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Xingang Fang, Yen Ting Chen, E. Hampton Sessions, Sarwat Chowdhury, Tomas Vojkovsky, Yan Yin, Jennifer R. Pocas, Wayne Grant, Thomas Schröter, Li Lin, Claudia Ruiz, Michael D. Cameron, Philip LoGrasso, Thomas D. Bannister, Yangbo Feng,